Private Advisory Group LLC Takes $987,000 Position in United Therapeutics Co. (NASDAQ:UTHR)

Private Advisory Group LLC acquired a new stake in shares of United Therapeutics Co. (NASDAQ:UTHR) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 2,753 shares of the biotechnology company’s stock, valued at approximately $987,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in UTHR. Trail Ridge Investment Advisors LLC lifted its holdings in United Therapeutics by 7.2% in the fourth quarter. Trail Ridge Investment Advisors LLC now owns 1,635 shares of the biotechnology company’s stock valued at $360,000 after acquiring an additional 110 shares during the period. Virtu Financial LLC bought a new position in shares of United Therapeutics in the 4th quarter worth approximately $1,353,000. Fisher Asset Management LLC boosted its holdings in shares of United Therapeutics by 5.8% in the fourth quarter. Fisher Asset Management LLC now owns 3,828 shares of the biotechnology company’s stock worth $842,000 after buying an additional 209 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund grew its position in United Therapeutics by 540.5% during the fourth quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 23,700 shares of the biotechnology company’s stock valued at $5,211,000 after buying an additional 20,000 shares during the period. Finally, PNC Financial Services Group Inc. grew its position in United Therapeutics by 6.6% during the fourth quarter. PNC Financial Services Group Inc. now owns 2,636 shares of the biotechnology company’s stock valued at $580,000 after buying an additional 164 shares during the period. Institutional investors own 94.08% of the company’s stock.

Insider Transactions at United Therapeutics

In related news, CFO James Edgemond sold 7,794 shares of the company’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $355.54, for a total value of $2,771,078.76. Following the completion of the sale, the chief financial officer now owns 5,344 shares in the company, valued at $1,900,005.76. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other United Therapeutics news, CEO Martine A. Rothblatt sold 269 shares of United Therapeutics stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $348.41, for a total value of $93,722.29. Following the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $45,293.30. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO James Edgemond sold 7,794 shares of the company’s stock in a transaction on Monday, October 7th. The stock was sold at an average price of $355.54, for a total value of $2,771,078.76. Following the transaction, the chief financial officer now directly owns 5,344 shares in the company, valued at $1,900,005.76. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 105,238 shares of company stock worth $35,612,493. Corporate insiders own 11.90% of the company’s stock.

United Therapeutics Trading Up 1.1 %

NASDAQ UTHR opened at $358.22 on Friday. United Therapeutics Co. has a one year low of $208.62 and a one year high of $366.08. The firm has a market cap of $15.94 billion, a price-to-earnings ratio of 16.46, a PEG ratio of 1.30 and a beta of 0.57. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.18 and a current ratio of 4.35. The firm has a 50 day simple moving average of $346.73 and a 200-day simple moving average of $303.39.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share for the quarter, missing the consensus estimate of $6.33 by ($0.48). United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The company had revenue of $714.90 million for the quarter, compared to analysts’ expectations of $691.87 million. During the same quarter in the prior year, the firm posted $5.24 EPS. The firm’s quarterly revenue was up 19.8% compared to the same quarter last year. Equities research analysts anticipate that United Therapeutics Co. will post 24.71 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Oppenheimer lifted their price target on shares of United Therapeutics from $400.00 to $575.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 28th. Wells Fargo & Company lifted their target price on United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a research report on Tuesday, August 20th. Jefferies Financial Group boosted their price target on United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a report on Monday, September 23rd. Morgan Stanley downgraded United Therapeutics from an “overweight” rating to an “equal weight” rating and raised their price objective for the stock from $310.00 to $321.00 in a research note on Thursday, July 11th. Finally, StockNews.com downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, August 2nd. One analyst has rated the stock with a sell rating, three have given a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $357.17.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.